Impact of concurrent remifentanil on the sedative effects of remimazolam, midazolam and propofol in cynomolgus monkeys

• Published in: European journal of pharmacology 2021-01, Vol.890, p.173639, Article 173639
• Main Authors: Kops, Maren S., Pesic, Marija, Petersen, Karl-Uwe, Schmalix, Wolfgang A., Stöhr, Thomas
• Format: Article
• Language: English
• Subjects: Cynomolgus monkey; Drug-drug interaction; Midazolam; Propofol; Remifentanil; Remimazolam
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2020.173639

Drug-drug interactions can substantially change pharmacological effects of the individual substances involved. For the use of sedatives or anaesthetics, having knowledge of the extent and characteristics of such interactions is crucial for ensuring the proper protection of patients undergoing any kind of sedation. Remimazolam is a new ultra-short acting benzodiazepine that is currently under development for intravenous use in procedural sedation and general anaesthesia. It exhibits a fast onset and fast offset which enables a more rapid recovery than currently available drugs in that class, such as midazolam. The purpose of this study was to more closely investigate the sedative properties and pharmacodynamic drug-drug interaction potential of remimazolam with the opioid analgesic remifentanil and compare it with other commonly used sedatives - midazolam and propofol. For this purpose, six Cynomolgus monkeys received escalating doses of remimazolam, propofol, and midazolam intravenously without or with concurrent remifentanil. Sedation was evaluated using a general sedation scale that included monitoring exploratory and avoidance behaviour, responses to sensory stimuli, posture and gait, and eyelid position as endpoints. Based on the results, sedative doses were calculated to allow evaluation of pharmacological drug-drug interaction with remifentanil. Remimazolam induced dose-dependent and consistent sedative effects in each endpoint tested and showed a high degree of synergism with remifentanil. Midazolam showed a comparable synergism while the interaction between propofol and remifentanil was less pronounced. •Remimazolam is a new potent sedative drug exhibiting a fast onset of broad sedation in Cynomolgus monkeys.•All endpoints of sedation (behaviour, stimuli response, posture/gait and ptosis) evolved consistently and dose-dependently.•Strong pharmacodynamic synergism with the opioid remifentanil was demonstrated.